{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:38:34Z","timestamp":1792013914877,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ophtha.2021.11.013","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T01:51:39Z","timestamp":1637027499000},"page":"520-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Anti\u2013Tumor Necrosis Factor \u03b1 versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6262-1740","authenticated-orcid":false,"given":"Mathilde","family":"Leclercq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Andrillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Maalouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"S\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bielefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8592-3810","authenticated-orcid":false,"given":"Julie","family":"Gueudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sen\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Moulinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Rouvi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"S\u00e8ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Desbois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Domont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Touhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-556X","authenticated-orcid":false,"given":"Carolla","family":"El Chamieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Biard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ophtha.2021.11.013_bib1","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","article-title":"Prevalence of noninfectious uveitis in the United States: a claims-based analysis","volume":"134","author":"Thorne","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2021.11.013_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/09273948.2016.1196713","article-title":"A\u00a0focus on the epidemiology of uveitis","volume":"26","author":"Tsirouki","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.ophtha.2021.11.013_bib3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ophtha.2015.10.028","article-title":"Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis","volume":"123","author":"Dick","year":"2016","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ophtha.2021.11.013_bib4","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1177\/1120672119899379","article-title":"Risk factors for ocular complications in adult patients with uveitis","volume":"30","author":"Prieto-Del-Cura","year":"2020","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.11.013_bib5","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2147\/OPTH.S180580","article-title":"Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges","volume":"13","author":"Massa","year":"2019","journal-title":"Clin Ophthalmol Auckl N Z"},{"key":"10.1016\/j.ophtha.2021.11.013_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000455279","article-title":"Insights into the physiopathology of inflammatory macular edema","volume":"58","author":"de Smet","year":"2017","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.11.013_bib7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2147\/DDDT.S166092","article-title":"Update in treatment of uveitic macular edema","volume":"13","author":"Koronis","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.ophtha.2021.11.013_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12974-018-1106-8","article-title":"Chronic exposure to tumor necrosis factor alpha induces retinal pigment epithelium\u00a0cell dedifferentiation","volume":"15","author":"Touhami","year":"2018","journal-title":"J\u00a0Neuroinflammation"},{"issue":"10","key":"10.1016\/j.ophtha.2021.11.013_bib9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/eye.2016.115","article-title":"Uveitic macular edema","volume":"30","author":"Fardeau","year":"2016","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.ophtha.2021.11.013_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4155\/tde-2019-0024","article-title":"Dexamethasone intravitreal implant (OZURDEX\u00ae) for macular edema secondary to noninfectious uveitis: a review of the literature","volume":"10","author":"Massa","year":"2019","journal-title":"Ther Deliv"},{"issue":"5","key":"10.1016\/j.ophtha.2021.11.013_bib11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ophtha.2020.08.035","article-title":"Seven-year outcomes of uveitic macular edema: the Multicenter Uveitis Steroid Treatment Trial and follow-up study results","volume":"128","author":"Tomkins-Netzer","year":"2021","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ophtha.2021.11.013_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/09273948.2012.665562","article-title":"Mycophenolate mofetil in the therapy of uveitic macular edema\u2014long-term results","volume":"20","author":"Doycheva","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"issue":"10","key":"10.1016\/j.ophtha.2021.11.013_bib13","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.ophtha.2014.04.023","article-title":"A\u00a0randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis","volume":"121","author":"Rathinam","year":"2014","journal-title":"Ophthalmology"},{"issue":"19","key":"10.1016\/j.ophtha.2021.11.013_bib14","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2017.5103","article-title":"Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis","volume":"317","author":"Kempen","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ophtha.2021.11.013_bib15","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10050","key":"10.1016\/j.ophtha.2021.11.013_bib16","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2021.11.013_bib17","first-page":"CD012577","article-title":"Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis","volume":"12","author":"Barry","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.ophtha.2021.11.013_bib18","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients","volume":"119","author":"D\u00edaz-Llopis","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ophtha.2021.11.013_bib19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/09273948.2018.1498110","article-title":"Infliximab and adalimumab in uveitic macular edema","volume":"26","author":"Lejoyeux","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2021.11.013_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary (month-6) outcomes of the STOP-Uveitis Study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with non-infectious uveitis","volume":"183","author":"Sepah","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2021.11.013_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2021.11.013_bib22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ophtha.2021.11.013_bib23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2021.11.013_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s00417-013-2552-8","article-title":"Anti-TNF-\u03b1 agents for refractory cystoid macular edema associated with noninfectious uveitis","author":"Schaap-Fogler","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2021.11.013_bib24","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/IAE.0000000000001690","article-title":"Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema","volume":"38","author":"Mesquida","year":"2017","journal-title":"Retina (Phila, Pa)"},{"key":"10.1016\/j.ophtha.2021.11.013_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2018.12.019","article-title":"Anti-i16-r tocilizumab in refractory and non-infectious uveitic cystoid macular edema. Multicenter study of 25 patients","volume":"200","author":"Vegas-Revenga","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2021.11.013_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/ICU.0000000000000466","article-title":"Cytokines in uveitis","volume":"29","author":"Weinstein","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.11.013_bib27","doi-asserted-by":"crossref","first-page":"579005","DOI":"10.3389\/fimmu.2020.579005","article-title":"Systemic regulatory T cells and IL-6 as prognostic factors for anatomical improvement of uveitic macular edema","volume":"11","author":"Matas","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ophtha.2021.11.013_bib28","doi-asserted-by":"crossref","first-page":"1623847","DOI":"10.1155\/2019\/1623847","article-title":"Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study","volume":"2019","author":"Bitossi","year":"2019","journal-title":"Mediators Inflamm"},{"issue":"12","key":"10.1016\/j.ophtha.2021.11.013_bib29","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1136\/bjophthalmol-2017-311234","article-title":"Adalimumab for the treatment of refractory active and inactive non-infectious uveitis","volume":"102","author":"Lee","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2021.11.013_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210799","article-title":"Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis","volume":"14","author":"Matas","year":"2019","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.ophtha.2021.11.013_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2014.10.013","article-title":"Uveitis in Beh\u00e7et disease in a tertiary center over 25 years: the KKESH Uveitis Survey Study Group","volume":"159","author":"Arevalo","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ophtha.2021.11.013_bib32","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/bjo.2007.123554","article-title":"Ocular features of Beh\u00e7et\u2019s disease: an international collaborative study","volume":"91","author":"Kitaichi","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2021.11.013_bib33","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ajo.2011.05.032","article-title":"Beh\u00e7et disease: visual prognosis and factors influencing the development of visual loss","volume":"152","author":"Taylor","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2021.11.013_bib34","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021009003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021009003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:11:28Z","timestamp":1758982288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642021009003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0161642021009003"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2021.11.013","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741194378.793593864","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti\u2013Tumor Necrosis Factor \u03b1 versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2021.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}